Showing results (391-400 of 757) with videos related to
Sort By:
Pageof 76
Journal of the American Heart Association|June 2, 2016
High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry DiseaseNora Seydelmann, Dan Liu, Johannes Krämer, et al.Journal of Medical Genetics|October 23, 2015
Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapyDavid G Warnock, Christie P Thomas, Bojan Vujkovac, et al.Medicine|May 26, 2018
Clinical impact of the alpha-galactosidase A gene single nucleotide polymorphism -10C>T: A single-center observational studyDaniel Oder, Dan Liu, Nurcan Üçeyler, et al.Kidney International Reports|August 4, 2023
Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)William G Herrington, Charlie Harper, Natalie Staplin, et al.Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography|July 2, 2011
Tei index in fabry diseaseMarkus Niemann, Frank Breunig, Meinrad Beer, et al.Advances in Therapy|May 28, 2025
Guideline-Recommended Disease-Modifying Therapies for Patients with Cardiorenal Disease: A Call-to-Action Narrative ReviewChristoph Wanner, Ming-Hui Zhao, Alpesh N Amin, et al.Open Heart|July 19, 2018
Association and diagnostic utility of diastolic dysfunction and myocardial fibrosis in patients with Fabry diseaseDan Liu, Daniel Oder, Tim Salinger, et al.Molecular Genetics and Metabolism|May 23, 2018
The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of expertsMarco Spada, Ralf Baron, Perry M Elliott, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 3, 2016
Performance of hemodialysis with novel medium cut-off dialyzersAlexander H Kirsch, Raphael Lyko, Lars-Göran Nilsson, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 9, 2021
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME TrialOdette S Reifsnider, Anuraag R Kansal, Christoph Wanner, et al.Pageof 76